Compare Invesco WilderHill Clean Energy ETF (PBW) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Invesco WilderHill Clean Energy ETF vs Sanofi SA — how do they compare? Invesco WilderHill Clean Energy ETF trades at $28.29 (market cap $347.46M), while Sanofi SA trades at $40.1 (market cap $96.81B). The key difference: Sanofi SA is far larger — about 278.6× Invesco WilderHill Clean Energy ETF's market cap, and Sanofi SA pays a 6.02% dividend while Invesco WilderHill Clean Energy ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Invesco WilderHill Clean Energy ETF for 46 Days and Sanofi SA for 94 Days on average.
| PBW | SNY | |
|---|---|---|
Market Cap | $347.46M | $96.81B |
Volume | 413,698 | 2,081,815 |
Sector | Sector/Thematic | Health |
52-Week High | $46.99 | $52.34 |
52-Week Low | $28.29 | $39.51 |
Typical Hold Time | 46 Days | 94 Days |
Enterprise Value | — | $116.20B |
Dividend Yield | — | 6.02% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
PBW, the Invesco WilderHill Clean Energy ETF, trades at $28.92, down 2.89% today amid a bearish technical signal from moving averages. The ETF's unique selection criteria prioritize ecological factors over financial metrics, resulting in concentrated exposure to the clean energy sector. Recent institutional selling, including a 96.3% reduction by IFP Advisors Inc. in Q2 2026 (SEC filing, September 18, 2026), reflects cautious sentiment despite long-term growth drivers like energy security and data center demand.
Outlook remains challenged by near-term volatility and sector underperformance versus broad markets, though global investment in clean energy offers structural tailwinds. Key risks include oil price swings, Fed policy impacts, and lack of diversification. Investors face a trade-off between speculative growth potential and elevated sensitivity to macroeconomic shifts.
Sanofi (SNY) trades at $40.23, up 1.69% with recent earnings beats and strong revenue growth to $46.72B in 2025. The stock shows bearish technical signals but maintains solid fundamentals with a 22.2 P/E ratio and 72.77% gross margin. Recent expansion of the Regeneron immunology alliance represents significant strategic positioning for future growth beyond Dupixent.
While near-term technical pressure exists, SNY's fundamental strength and pipeline development provide long-term upside potential. Key risks include patent expiration concerns and competitive pressures in the pharmaceutical sector. Analyst consensus leans slightly positive with 44% buy ratings, though institutional sentiment remains cautious given technical indicators.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Invesco WilderHill Clean Energy ETF
PBW is an equal-weighted ETF that invests in U.S. companies leading the clean energy transition. It focuses on renewable energy, power conservation, and sustainable technologies like solar, wind, and energy storage.
Read more on PBW →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
